Vibalogics Completes 118,000 ft² GMP Facility in Massachusetts Establishing Global Capabilities

Published: 20 December 2021

New Massachusetts facility enables focused end-to-end virotherapy CDMO services

Today, Vibalogics celebrates completion of the first phase of construction of its new state-of-the-art live virus and viral-vector facility at 1414 Massachusetts Ave. Boxborough, MA. The opening comes in record time just 13 months after signing a long-term lease agreement with Lincoln Property Company for the company’s 118,000 ft² facility and first U.S.-based location since Vibalogics was established in 2002 (Bioprotect Research GmbH).

The company selected the 145-acre campus in Boxborough as home of its first United States location, new global headquarters and GMP facility to accelerate market supply of process & analytical development, manufacturing, testing, and aseptic fill-finish services to oncolytic virus, viral vector gene therapy and vaccine drug development companies during early-to-late phase clinical trials and commercial market approval.

“The Virotherapy industry has been challenged in recent years, as specialized CDMOs have experienced unprecedented demand resulting in substantial wait times to customers needing access to manufacturing capacity. Vibalogics’ U.S. facility and brownfield-style project quickly enabled the company to bring much-needed additional supply to its customers and market for many years to come. Boxborough’s location in the Greater Boston suburbs has also provided the company and its employees many benefits, including a great work environment, local access to talent, frequently reduced daily commute times as compared to Boston-Cambridge based jobs, and as such, steady onboarding of focused personnel needed to quickly establish our operations.” says Tom Hochuli, Chief Executive Officer.

The project was made successful through the collaboration with multiple partners including Cardinal Group USA (Woburn, MA) who helped to manage the overall project including demolition, construction, as well as DPS Engineering (Framingham, MA) who supplied consulting and design services for the site’s process development and quality control laboratories. Critical to rapid completion of the project was the relationship with industry modular cleanroom supplier Germfree Laboratories, Inc. (Oranta Beach, FL) who provided Vibalogics with off-site construction of the facility’s BSL-2 GMP manufacturing environment.

“The decision to utilize modular clean rooms advanced Vibalogics’ Phase 1 operations by multiple months – as demolition and construction occurred in Boxborough, our cleanroom manufacture was taking place at Germfree. The concept provides the company’s customers with a flexible, single-use manufacturing environment, and opportunity to quickly scale out with late-phase and commercial demand into the site’s expansion areas.” shares Tim Rossini, Sr. Director, Engineering and Site Technological Services. Ahead, Vibalogics’ future site plans benefit from an ongoing relationship with the modular supplier, which is considered to support its’ Phase 2 and Phase 3 construction of additional GMP capacity, projected for 2022 and 2023.

This major company milestone is a part of Vibalogics’ multi-year strategic build of its business offering global virotherapy services for industry partners. The company is in the middle of a three-year investment plan, which further includes active expansion of the 100,000 ft² (9,400 m²) clinical facility in Cuxhaven, Germany soon to open its 6th building with added GMP cleanrooms and support areas.

Made possible through robust facility infrastructure and over $200 million in planned investment, Vibalogics is focused on fee-for-service operations, as well as client-dedicated and custom construction fit-outs for customers with unique manufacturing needs in industry. The company’s additional plans include continued redevelopment of the sites, procurement of innovative new equipment, ongoing recruitment of expert personnel & advisory, and development of next-generation production processes for the emerging virotherapy market.

About Vibalogics

For the past 15+ years Vibalogics has specialized in servicing the life sciences market by pioneering efficient, economically viable, and GMP compliant manufacture of complex oncolytic viruses, viral vector gene therapies and vaccines, enabling its customers to deliver transformational products to patients worldwide. Vibalogics is wholly owned by Ampersand Capital Partners, a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector, since 1988. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.

For further information, images and interview opportunities, please contact Lara Lovenbury at ramarketing: | +44 (0)7972471903 | | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing

We’re the ideal CDMO for your Manufacturing project

Get in touch


What to read next

Lab Manager: Virotherapy GMP Site Expands …

Stefan Beyer, PhD, President and Managing Director recently sat down with Lab Manager to discuss ongoi…

Vibalogics Establishes Scientific Advisory…

Vibalogics, a global contract development and manufacturing organization (CDMO) and recognized leader …

Vibalogics Appoints Global CEO to Lead U.S…

Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in th…